In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vifor Pharma Group

http://www.viforpharma.com/

Latest From Vifor Pharma Group

Vifor Bulks Up Renal Franchise With Sanifit And Inositec Acquisitions

A couple of months after licensing the late-stage kidney disease drug sparsentan from Travere, the Swiss group has beefed up its nephrology activities by buying Mallorca-based Sanifit and Swiss outfit Inositec.

M & A Renal

Novartis’s Iptacopan Pulls Ahead In Race To Fill Nephrology Unmet Need

The first-in-class candidate met two primary endpoints in a Phase II trial for C3 glomerulopathy, suggesting potential edge over ChemoCentryx and Vifor’s competitor avacopan.

Renal Clinical Trials

Vifor/Angion Collaboration On Rocky Ground As ANG-3777 Phase III Trial Fails In Kidney Transplant Patients

Vifor and Angion’s ANG-3777 has failed in a Phase III trial for kidney transplant patients at risk of delayed graft function less than a year after the companies sealed a $80m licencing deal for the product. As focus shifts to another rare nephrological indication, analysts express skepticism.

Clinical Trials Companies

Gilead Awaits EMA Verdict On Trodelvy As It Whizzes Through EU Review

Sponsors of six new products, including a first-in-class treatment for unresectable locally advanced or metastatic triple-negative breast cancer, will find out this week if their products are on course to be approved for use in the EU. Also, two sponsors might be asked to address last-minute questions about their drugs.

Approvals Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
    • Galenica Group
    • Relypsa, Inc.
    • Vifor Pharma
    • Vifor-Fresenius Medical Care Renal Pharma Ltd.
    • OM Pharma
UsernamePublicRestriction

Register